SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "L773:1945 7197 srt2:(2000-2004)"

Sökning: L773:1945 7197 > (2000-2004)

  • Resultat 1-10 av 102
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  •  
2.
  •  
3.
  • Andersson, Björn, et al. (författare)
  • Raloxifene does not affect insulin sensitivity or glycemic control in postmenopausal women with type 2 diabetes mellitus: a randomized clinical trial.
  • 2002
  • Ingår i: The Journal of clinical endocrinology and metabolism. - : The Endocrine Society. - 0021-972X .- 1945-7197. ; 87:1, s. 122-8
  • Tidskriftsartikel (refereegranskat)abstract
    • Little is known about the metabolic or cardiovascular effects of selective ER modulators (SERMs), such as raloxifene hydrochloride (RLX), in postmenopausal women with type 2 diabetes mellitus (DM). Therefore, the effect of RLX vs. placebo (PL) on glycemic control, insulin sensitivity, as well as effects on a number of hormone, lipid, coagulation, and safety factors were determined in 30 postmenopausal women with type 2 DM in a randomized, double blind, cross-over trial. All participants had a SHBG serum concentration below 60 nmol/liter at baseline and had stable diabetes controlled by either oral hypoglycemic agents or diet for 1 month. In the first treatment period, participants received 12 wk of either PL or RLX, followed by an 8-wk washout before the second treatment period. In the second treatment period, participants were crossed over to the other treatment. Compared with PL, RLX did not significantly affect fasting blood glucose, hemoglobin A(1c), lipids, fasting insulin, or insulin sensitivity (as measured by the euglycemic clamp technique). Compared with PL, RLX reduced fibrinogen levels by 0.77 g/liter (P < 0.001), IGF-I by 2.4 nmol/liter (P < 0.001), and free T by 0.73 pmol/liter (P = 0.038) and increased SHBG by 5.5 nmol/liter (P = 0.001) and IGF-binding protein-3 by 0.57 ng/ml (P = 0.007). Our results demonstrate that RLX does not significantly affect glycemic control and has favorable or neutral effects on selected surrogate markers of cardiovascular risk in postmenopausal women with type 2 diabetes mellitus while decreasing hyperandrogenicity in these patients.
  •  
4.
  • Ankarberg-Lindgren, Carina, 1963, et al. (författare)
  • Nocturnal application of transdermal estradiol patches produces levels of estradiol that mimic those seen at the onset of spontaneous puberty in girls.
  • 2001
  • Ingår i: The Journal of clinical endocrinology and metabolism. - 0021-972X .- 1945-7197. ; 86:7, s. 3039-44
  • Tidskriftsartikel (refereegranskat)abstract
    • The objective of pubertal induction in children with hypogonadism is to mimic spontaneous puberty in terms of physical and psychological development. In a clinical observation study, we induced puberty in 15 girls with hyper- or hypogonadotropic hypogonadism using low doses of transdermal estradiol patches attached only during the night and compared the estradiol concentrations obtained with those in healthy girls. Pubertal induction was started between the ages of 12.3 and 18.1 yr. A transdermal matrix patch of 17beta-estradiol (25 microg/24 h; Evorel, Janssen Pharmaceuticals-Cilag) was cut into pieces corresponding to 3.1, 4.2, or 6.2 microg/24 h initially and attached to the buttock. After 4-14 months, the dose was increased gradually. Serum 17beta-estradiol concentrations were measured every 2 h by RIA (detection limit, 6.0 pmol/L; 1.6 pg/mL). The results show that it is possible to mimic the spontaneous levels as well as the diurnal pattern of serum 17beta-estradiol in early puberty, by cutting a transdermal 17beta-estradiol matrix patch and attaching a part of it, corresponding to 0.08-0.12 microg estradiol/kg BW, to the buttock nocturnally. In most of the girls, breast development occurred within 3-6 months of the start of treatment.
  •  
5.
  •  
6.
  • Aschim, EL, et al. (författare)
  • Linkage between cryptorchidism, hypospadias, and GGN repeat length in the androgen receptor gene
  • 2004
  • Ingår i: Journal of Clinical Endocrinology and Metabolism. - : The Endocrine Society. - 1945-7197 .- 0021-972X. ; 89:10, s. 5105-5109
  • Tidskriftsartikel (refereegranskat)abstract
    • Although sufficient androgen receptor (AR) function is crucial for normal male sexual differentiation, single-point mutations in the AR gene are infrequent in the two most common male congenital malformations, hypospadias and cryptorchidism. Because polymorphic CAG and GGN segments regulate AR function, we investigated whether there was any association between these polymorphisms and mentioned malformations. Genotyping was performed by direct sequencing of DNA from patients diagnosed with hypospadias (n = 51) and cryptorchidism ( n = 23) and controls ( n = 210). The subjects with hypospadias were divided into subgroups of glanular, penile, and penoscrotal hypospadias. Median GGN lengths were significantly higher ( 24 vs. 23) among both subjects with cryptorchidism, compared with controls ( P = 0.001), and those with penile hypospadias, compared with either controls ( P = 0.003) or glanular and penoscrotal hypospadias combined ( P = 0.018). The frequency of cases with GGN 24 or more vs. GGN = 23, differed significantly among those with cryptorchidism (65/35%), compared with controls (31/54%) ( P = 0.012), and among subjects with penile hypospadias (69/31%), compared with either controls ( P = 0.035) or glanular or penoscrotal hypospadias combined (32/55%) ( P = 0.056). There were no significant differences in CAG lengths between the cases and controls. Our findings indicate an association between GGN length and the risk of cryptorchidism and penile hypospadias, both conditions considered consequences of low androgenicity.
  •  
7.
  •  
8.
  •  
9.
  • Bengtsson, B A, et al. (författare)
  • Treatment of growth hormone deficiency in adults.
  • 2000
  • Ingår i: The Journal of clinical endocrinology and metabolism. - : The Endocrine Society. - 0021-972X .- 1945-7197. ; 85:3, s. 933-42
  • Tidskriftsartikel (refereegranskat)abstract
    • In analogy with other hormonal replacement therapy GH treatment should be commenced with a low starting dose, independent of body weight or body surface area. Hormonal replacement should mimic the normal physiology to minimize the risk of side effects in the life-long replacement of adults. We should, therefore, consider individual responsiveness and also be aware of the difference between pattern of GH under normal condition and during s.c. administration. The safety and monitoring of GH replacement therapy in adults have been addressed in the Growth Hormone Research Society Consensus Guidelines for Diagnosis and Treatment of Adults with GH Deficiency from the Port Stephens Workshop, April 1997. Besides finding better and more accurate biochemical markers for choosing correct GH replacement dose, future research should address the long-term benefits and safety with GH replacement in adults, with special emphasize on incipient risks in terms of cardiovascular disease and of neoplasia, in particular.
  •  
10.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-10 av 102
Typ av publikation
tidskriftsartikel (101)
forskningsöversikt (1)
Typ av innehåll
refereegranskat (100)
övrigt vetenskapligt/konstnärligt (2)
Författare/redaktör
Johannsson, Gudmundu ... (11)
Groop, Leif (7)
Kämpe, Olle (7)
Arner, P (5)
Erfurth, Eva Marie (5)
Ahren, Bo (4)
visa fler...
Wedell, A (4)
Olsson, Tommy (4)
Perheentupa, Jaakko (4)
Rorsman, Fredrik (4)
Söderberg, Stefan (4)
Tuomi, Tiinamaija (3)
Stibrant Sunnerhagen ... (3)
Hagmar, Lars (3)
Landin-Olsson, Mona (3)
Gustafsson, Jan (3)
Hoffstedt, J (3)
Husebye, Eystein S. (3)
Rask, Eva, 1958- (3)
Husebye, ES (3)
Bengtsson, B A (3)
Svensson, J (2)
Giwercman, Aleksande ... (2)
Bengtsson, Bengt-Ake (2)
Ryden, M (2)
Albertsson-Wikland, ... (2)
Svensson, Johan, 196 ... (2)
Bengtsson, Bengt-Åke ... (2)
Almgren, Peter (2)
Hamsten, A (2)
Landin-Olsson, M (2)
Skogseid, Britt (2)
Björk, Jonas (2)
Malmström, Anders (2)
Albertsson Wikland, ... (2)
Mikoczy, Zoli (2)
Svensson, Johan (2)
Westin, Gunnar (2)
Sköldberg, Filip (2)
Bolinder, J (2)
Wahrenberg, H (2)
Arnqvist, Hans, 1943 ... (2)
Walker, Brian R (2)
Giwercman, Yvonne (2)
Andrew, R (2)
Sennstrom, M (2)
Bengtsson, B (2)
Lajic, S (2)
Lovas, K (2)
Ritzen, EM (2)
visa färre...
Lärosäte
Karolinska Institutet (39)
Lunds universitet (31)
Göteborgs universitet (17)
Uppsala universitet (17)
Umeå universitet (11)
Linköpings universitet (5)
visa fler...
Örebro universitet (4)
Gymnastik- och idrottshögskolan (1)
visa färre...
Språk
Engelska (102)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (53)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy